<DOC>
	<DOCNO>NCT00278109</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , cyclophosphamide doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together cyclophosphamide doxorubicin surgery may kill tumor cell remain . PURPOSE : This phase I/II trial study side effect radiation therapy give together cyclophosphamide doxorubicin see well work treat woman stage I stage II breast cancer undergone surgery .</brief_summary>
	<brief_title>Radiation Therapy , Cyclophosphamide , Doxorubicin Treating Women With Stage I Stage II Breast Cancer Who Have Undergone Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Assess potential acute late skin subcutaneous toxicity woman resect stage I II breast cancer treat partial breast irradiation ( PBI ) concurrent cyclophosphamide/doxorubicin ( AC ) chemotherapy . - Assess cosmetic effect partial breast irradiation/chemotherapy ( PBIC ) patient . - Assess local control rate patient treat regimen . OUTLINE : Patients undergo partial breast radiotherapy daily , 5 day week , 3 week . Patients also receive doxorubicin IV 15 minute cyclophosphamide IV 30 minute day 1 . Treatment doxorubicin cyclophosphamide repeat every 2 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically approximately 10 year . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast routine hematoxylin eosin ( H &amp; E ) stain Primary tumor ≤ 4 cm 03 positive axillary lymph node ( pathologic T12 , pathologic N0N1 , M0 ) Patients lymph node positive cytokeratin staining ( i.e. , H &amp; E negative ) eligible No squamous cell carcinoma sarcoma breast Patients must undergo segmental mastectomy ( SM ) level I axillary dissection sentinel lymph node biopsy within past 14 week Surgical margin time SM must negative ( &gt; 3 mm ) invasive carcinoma noninvasive ductal carcinoma No active localregional disease Hormone receptor status specify PATIENT CHARACTERISTICS : ECOG performance status 01 Sex : female Menopausal status specify Not pregnant Negative pregnancy test Fertile patient must use effective nonhormonal contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No serious poorly control medical psychiatric condition could exacerbate , complicate compliance study treatment PRIOR CONCURRENT THERAPY : No prior radiation therapy breast No prior trastuzumab ( Herceptin ® ) No concurrent chemotherapy No concurrent hormonal therapy except follow : Steroids give adrenal failure Hormones administer nondiseaserelated condition ( e.g. , insulin diabetes , synthroid hypothyroidism ) Intermittent dexamethasone antiemetic premedication</criteria>
	<gender>Female</gender>
	<minimum_age>39 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>